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Summary 
In our studies of host defense  to the intracellular protozoan Leishmania  major,  we uncovered 
a novel mechanism of antileishmanial defense that involves direct cell contact between effector 
CD4 § lymphocytes and Leishmania-infected  macrophages. The mechanism is distinctive because 
it does not involve lymphokine secretion and induces no cytotoxic effects in the host cells; its 
expression is antigen-specific and genetically restricted. We now demonstrate that these effector 
CD4 § cells display tumor necrosis factor (TNF) on their surface and provide evidence that the 
membrane-associated TNF is involved in the activation of the antileishmanial defense.  Using 
a Leishmania-specific cloned T-T cell hybridoma line (1B6; CD4 +, T helper type 1) that activates 
antileishmanial defense in macrophages through cell contact and does not secrete TNF, we noted 
that only cells bearing surface TNF (TNF+), but not ones lacking surface TNF (TNF-), exerted 
these effects. Moreover, the antileishmanial  effects exerted by TNF + 1B6 cells as well as by lymph 
node CD4 + TNF + lymphocytes could be blocked with anti-TNF antibody. We propose that 
membrane-associated TNF on CD4 § T cells may provide a mechanism of targeting activation 
signals  to macrophages in an antigen-specific and genetically restricted manner. 
ntimicrobial effects can be induced in infected macrophages 
by lymphocytes that recognize specific microbial antigens 
and are syngeneic with the macrophages (1). Soluble macro- 
phage-activating  lymphokines  (MAFs) 1 released  by  these 
lymphocytes are known to be instrumental in such defense 
(2,  3).  Lymphocyte-mediated  activation  of  antimicrobial 
defenses in macrophages also may occur via interactions that 
do not involve lymphokine  secretion (4,  5).  In our studies 
on activation of antileishmanial defense, we serendipitously 
encountered  a  process  of CD4 §  T  lymphocyte-mediated 
macrophage activation that occurs without MAF secretion, 
is not cytotoxic to host cells, and requires  intimate contact 
between effector lymphocytes and target macrophages (6-9). 
Until recently,  the membrane-associated  effector molecule(s) 
involved in this defense remained obscure.  The demonstra- 
tion that TNF has macrophage-activating properties  (10-12), 
and exists in both a soluble and a membrane-anchored form 
(13-15), led us to consider membrane TNF as a possible effector 
molecule  in the defense we were investigating. 
Materials and Methods 
Parasites.  Leishmania  major, NIH Seidman strain (WHO strain 
designation, MHOM/SN/74  Seidman), was originally isolated by 
i Abbreviation used in this paper: MAF, macrophage-activating  lymphokine. 
one of us (DJ.  Wyler) from a Peace Corps volunteer in Senegal 
(16). Amastigotes were propagated in mice by serial infection and 
were obtained from infected footpad tissue, as described (6). 
Mice.  Female  BALB/cAnNTacfBr  (amastigote  donor), C57BL/ 
6TacfBr, and B6C3F1 (macrophage and lymphocyte donors) mice 
were obtained from Taconic (Germantown, NY). 
Effector T  Cells.  T lymphocytes were derived from draining 
popliteal lymph nodes excised  from C57BL/6 mice infected for 4-5 
wk with L.  major (6). The  1B6 hybridoma cell line (a cloned 
Leishmania-specific CD4 + CD3 + Thl hybridoma line, I-A  b/k re- 
stricted, [91) was originally produced from the lymph node T lym- 
phocyte population without prior in vitro expansion and was cloned 
by customary methods (17). 
Antibodies and Flow Cytometry.  The anti-murine TNF-ol anti- 
body (rabbit hyperimmune serum) was obtained from Genzyme 
(Boston, MA). For isolation of CD4 § cells, anti-L3T4 antibody 
(rat IgG2b-PE conjugate) from Becton Dickinson Immunocytom- 
etry Systems (Mountain View, CA) was used. For indirect im- 
munofluorescence,  FITC-conjugated goat anti-rabbit IgG (affinity 
purified) from Fisher Scientific  (Pittsburgh, PA; Southern Biotech- 
nology Associates, Inc., Birmingham, AL) was used. For blocking, 
normal goat (S-2007) and normal rat (S-2757) serum from Sigma 
Chemical Co. (St. Louis, MO) was used. All staining for FACS  | 
analysis was carried out in the presence of 0.1% NAN3; dead cells 
were eliminated from  analysis after DNA  staining with  1 #g 
propidium iodide. The cells were sorted on a FACS Star Plus  | 
(Becton Dickinson & Co., Mountain View, CA) or a Coulter Epics 
541 Series flow cytometer (Coulter Scientific  Instruments, Hialeah, 
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TNF, as determined by analysis  of immunofluorescence  histograms, 
was never >1-2% between either instrument. 
Assay for Antileishmanial Activity.  The ability of 1B6 cells to 
activate Leishmania-infected macrophages was assessed  by our pub- 
lished methods (6). Resident macrophages from uninfected mice 
(B6C3F1 strain; Taconic) were harvested  by peritoneal lavage  with 
divalent cation-deficient HBSS. Peritoneal cells were washed and 
resuspended in supplemented  ILPMI  1640 containing 10% FCS (Hy- 
clone Laboratories, Logan, UT),  5  x  10 .5 M 2-ME, penicillin 
(100 U/ml), streptomycin (100/~g/ml), and 4 mM L-glutamine. 
2  x  10  s peritoneal cells were combined with 2-4  x  10  s Leish- 
mania amastigotes in a total volume of 0.8 ml in 12  x  75-mm 
propylene tubes (No. 2063; Falcon Labware, Becton Dickinson & 
Co., Lincoln, NJ). Effector T lymphocytes were added to infected 
macrophages 24 h later (one to two hybrid cells per macrophage; 
two to five  lymphocytes  per macrophage). The suspension cultures 
were then incubated for an additional  48 h at 37~  with or without 
the addition of anti-TNF-c~ antibody (1:100 dilution of hyperim- 
mune serum). Cells were harvested onto glass slides by cytocen- 
trifugation (Shandon-Southem,  Sewickly,  PA) and were stained  with 
Wright's-Giemsa (Diff-Quick, Dade Diagnostics, Aquada, PR). 
The percentage of infected macrophages and the mean number of 
amastigotes  per infected macrophage were determined microscopi- 
cally. 100 macrophages in remote fields  were scored; mean _+ SEM 
of amastigotes per 100 macrophages in triplicate culture with or 
without the addition of lymphocytes  was compared  by using a one- 
tailed Student's t test. The antileishmanial  effect  was calculated  from 
the raw data to express the percentage reduction in parasites per 
100 macrophages  cultured with lymphocytes  compared to ones cul- 
tured without. 
Preparation of Fixed Cells.  Cells  that were fixed were treated 
with a 1% paraformaldehyde  solution in HBSS for 15 rain at room 
temperature. The paraformaldehyde  was removed,  and the cel/s  were 
washed three times with HBSS. After the third wash, the cells  were 
incubated in supplemented culture medium for 30 min at 37~ 
This incubation period was necessary  to remove residual amounts 
of paraformaldehyde.  The cells were washed three more times and 
were used without further treatment. 
Preparation of Cell Membrane Lysates.  1B6 cells were stimulated 
with Con A (5 mg/ml; Miles Laboratories, Kankakee, IL) and 
anti-murine  CD3 mAb (hamster IgG, 10 mg/ml; PharMingen, 
San Diego, CA) for 12-18 h in supplemented media at 37~  Stim- 
ulation under these conditions was used to avoid contamination 
with macrophages if used as stimulator cells. After stimulation, 
cells were washed three times with PBS. 106 cells were lysed for 
1-2 h at 4~  in lysis buffer containing 1% Triton X-100, 10 mM 
Hepes at pH 7.4, 200 mM NaC1, 2 mM CaC12, 2.5 mM MgC12, 
and protease inhibitors, which included 2 mM chymostatin, 5 mM 
leupeptin, 10 mg/ml soybean trypsin inhibitor, 10 mM iodoacet- 
amide, 10 mM EDTA, 0.02% NAN3, and 1-2 mM PMSF. Cell ly- 
sates were centrifuged at 32,000 g in an ultracentrifuge with a 70 
Ti rotor (Beckman Instruments, Palo Alto, CA) for 1 h at 10~ 
to  sediment nuclear and other cellular debris. The membrane 
protein-enriched fraction was suspended in 1 ml of buffer and as- 
sayed as described. 
Immunological Assay.for TNF~.  An ELISA (Genzyme) using 
mAb specific for murine TNF-cr  which has been previously de- 
scribed (18), was used to quantify the amount of TNF present in 
culture supernatants of 1B6 T hybridoma cells. A standard curve 
for each assay was generated with known concentrations of mu- 
rine TNF-c~ containing 0, 50, 100, 200, 400, 800, 1,600, and 3,200 
pg/ml (concentrations defined according to the manufacturer). 
Western Blot Analysis.  A total of 107 1B6 cells were lysed for 
1-2 h at 4~  in lysis buffer containing protease inhibitors. Cell 
lysates were centrifuged at 32,000 g in an ultracentrifuge with a 
70 Ti rotor (Beckman Instruments) for 1 h at 10~  to sediment 
nuclear and other cellular debris. The membrane protein-enriched 
pellet after high speed centrifugation (55,000 g, 2 h) was then ex- 
tracted and reduced in sample buffer containing 150 mM "Iris at 
pH 6.8, 10% SDS, 10% glycerol, 10% 2-ME, and 0.015% pyronin 
Y. The sample was boiled for 5 min before  loading onto a SDS/15% 
polyacrylamide  get. Gel electrophoresis and Western blot analysis 
were done essentially  as described  (19, 20). The immunoblots were 
developed with the rabbit anti-murine TNF-o~ antibody and alka- 
line phosphatase-labeled  goat anti-rabbit IgG (Proto Blot System; 
Promega Corp., Madison, WI), as described (21). 
Results and Discussion 
Activation  of Antileishmanial  Effects by T  Cell Hybridomas 
Is Inhibited by Anti-TNF-c~ Antibody.  Using published methods 
(17),  we  prepared  and doned  T-T  cell  hybridomas from 
popliteal lymph node lymphocytes of mice with hind footpads 
infected  with  Leishmania  major. We  selected  done  1B6 
(CD4 +) for its failure to secrete MAFs and its ability in vitro 
to induce antileishmanial effects in L. major-infected macro- 
phages (9).  When we added polydonal rabbit anti-murine 
TNF-c~ antibody (IgG) to cocultures of 1B6 cells and infected 
macrophages, the antileishmanial effects of the T  cell were 
abrogated (Fig.  1 a); nonimmune rabbit IgG had no effect 
in this assay (data not shown). 
1B6 Hybridoma Cells Extrress TNF on Their Cell SuCac~  We 
determined by fluorescence flow cytometric analysis with anti- 
TNF that 40-60% of the 1B6 cells expressed TNF on their 
surface (six experiments). Interestingly, when these hybridoma 
cells were isolated by FACS  |  only the TNF + (and not the 
TNF-)  population induced antileishmanial effects  in cul- 
tures of infected macrophages (Fig.  1 a);  these effects were 
markedly reduced in the presence of anti-TNF antibody. Par- 
ticularly noteworthy was  our  observation  that when  the 
TNF-  1B6 cells were maintained in culture for 3-7 d after 
the initial sorting and were then reanalyzed, 40-60% of the 
cells had become TNF + and the population concomitantly 
had  acquired  the  ability to  induce antileishmanial effects 
(Fig.  1 b). After incubating for 3-7 d, the sorted cells that 
were initially 96.5% TNF § , were also noted to be 40-60% 
TNF +. 
1B6 Hybridoma Cells Stimulated by Leishmania-infected Mac- 
rophages Do Not Secrete TNE  The correlation of membrane 
expression  of TNF on 1B6 cells and the ability of the cells 
to exert an antileishmanial effect as revealed by cell sorting 
studies strongly suggested that surface TNF was involved 
in the macrophage activation process.  We found that  1B6 
cells do not secrete TNF when cocultured with infected mac- 
rophages. In the coculture supernatants of viable  1B6 cells 
that were coincubated with live infected macrophages, we 
could detect TNF activity (250-500 pg/ml; limit of sensi- 
tivity, 50 pg/ml; measured by a TNF-specific ELISA [Table 
1] and by L929 cytotoxicity  assay; reference 22). When, how- 
ever, live 1B6 cells were coincubated with paraformaldehyde- 
fixed macrophages (1% paraformaldehyde, washed extensively 
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Figure  1.  (a) Effects of anti-TNF antibody on the ability of the 1B6 hybridoma clone to induce antileishmanial defense in vitro. 1B6 cells (T cell 
hybridoma specific for Leiskmania; I-A  b/k restricted; reference 9) were added to syngeneic (B6C3F1) peritoneal macrophages infected for 24 h with 
L. major  at a parasite/macrophage ratio of 2:1. Cocultures were maintained for 48 h with or without the addition of anti-TNF-c~ antibody (TNF AB; 
rabbit hyperimmune serum, 1:100 dilution). TNF-expressing 1B6 cells were enriched (96.5 +  1.8% positive, mean _+ SE; three experiments) or depleted 
(97.9 _+ 1.3% negative) by FACS  |  using anti-TNF antibody. Control cultures of infected macrophages were maintained without lymphocytes in medium 
alone or with anti-TNF antibody. Data were derived from triplicate determinants in a representative experiment of six performed. (b) Effects of anti-TNF 
antibody on the ability of sorted and recultnred 1B6 hybridoma done to induce antileishmanial defense in vitro. 1B6 cells were enriched or depleted 
for surface TNF by FACS  |  Aliquots of the cells were either tested immediately in the antileishmanial defense assay or were incubated alone for an 
additional 4--7 d before testing (cultured). Flow cytometry revealed that after reculture of the originally TNF- population, 40-60% of the 1B6 cells 
expressed TNF on their surface. Data are shown for triplicate determinations in a representative experiment of three performed. 
in HBSS, and subsequently in supplemented media), we could 
detect  no  TNF  activity in  the  coculture  supernatants.  On 
the other hand, using these assays, we could detect TNF ac- 
tivity (100-300 pg/ml [equivalent to the membrane protein- 
Table  1.  TNF Level Present in Cell-flee Supernatants from 
Cultures of lB6 T Hybridoma Cells under Various Culture Conditions 
Supernatant*  TNF+ 
pg/ml 
M~I alone  10  _+  7 
1B6  alone  0  +- 0 
Mr  +  1B6 s  340  +_  55 
Fixed Mr  +  1B611  0  +  0 
1B6  cell  membrane lysate~  225  _+  65 
Mr  +  fixed  1B6  690  _+  160 
An ELISA using a mAb specific for murine TNF-c~ that has been previ- 
ously described (25) was used to quantify the amount of TNF present 
in culture supernatants of 1B6 T  hybridoma cells. 
* Tested as a final dilution of 1:2. Mr  Leishmania-infected  macrophages. 
+ Mean  _+ SEM; three separate experiments. 
S Viable hybridomas were added to live 24-h infected macrophages at a 
2:1 E/T cell ratio. 
II Cells that were fixed were treated with a 1% paraformaldehyde solu- 
tion in HBSS and extensively washed before use. 
1B6 cells were  stimulated with Con A (5 #g/ml) and anti-murine 
CD3 mAb (hamster IgG, 10/zg/ml) for 12-18 h in supplemented media 
at 37~  After stimulation,  ceils were washed and were lysed in lysis 
buffer containing  protease  inhibitors.  After  isolation,  the  membrane 
protein-enriched fraction of the total cell ]ysate was suspended in 1 ml 
of buffer and assayed as described. 
enriched  fraction of the  total cell lysate suspended  in  1 ml 
derived  from  a  total  of  10  6 cells])  in  the  cell  membrane 
protein-enriched fraction prepared from 1B6 ceils after a 12- 
18  h  stimulation  with  Con  A  (5  #g/ml)  and  anti-murine 
CD3  mAb  (hamster  IgG,  10/zg/ml).  Furthermore,  para- 
formaldehyde-fixed  1B6 cells could trigger infected macro- 
phages to secrete 0.5-1.0 ng/ml TNF into the culture super- 
natants (Table 1).  These observations indicate that 1B6 cells 
express  TNF  on  their  surface but  do  not  secrete  TNE 
T Hybridoma Cell Surface TNF Is "o50-60 kD  Since the 
secreted  form  of TNF  has  a Mr  ,,o17  kD  (13),  whereas  T 
lymphocyte membrane-anchored TNF has a Mr ,,o50-60 kD 
(15, 23), we carried out studies to determine the Mr of 1B6- 
associated TNF.  1B6 cells were incubated for 12-18 h in the 
presence of 5 #g/ml Con A and 10/xg/mt anti-murine CD3 
antibody,  after which  the membrane protein-enriched  frac- 
tion of the total cell lysate was prepared,  detergent  solubi- 
lized, subjected to electrophoresis under reducing conditions, 
and finally analyzed by Western blot methods using anti-TNF 
antiserum.  A  single  protein  band,  migrating  with  a  Mr 
"-46-69  kD,  was identified  (Fig.  2,  lane  b).  In related  ex- 
periments,  1B6  cells  were  metabolically  labeled  with  35S- 
methionine  and  3SS-cysteine.  A  single protein band with  a 
M~  ,,o46-69  kD  was  immunoprecipitated  from  membrane 
protein-enriched  fractions  of 35S-labeled  cells  with  TNF- 
specific antibodies  (data not shown).  In neither experiment 
did normal rabbit serum identify any 1B6-associated proteins. 
These  findings  indicate  that  1B6  synthesize  the  large M~ 
TNF that has been identified as the membrane anchored form 
(15,  23). 
Effector CD4 + T Lymphocytes from Leishmania-infected Mice 
Induce Antileishmanial  Effects in MacroFhages by Cell Surface 
TNE  We extended our observations with the 1B6 T-T hy- 
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membrane  proteins probed with  anti-murine 
TNF-c~ antibody. Total cell lysates enriched for 
cell membrane proteins derived from a total of 
107 1B6 cells were subjected  to electrophoresis 
in  each  lane  and  immunoblotted with  either 
normal  rabbit serum  (lane  a)  or  anti-murine 
TNF-c~ antiserum (lane b). The migration posi- 
tions of phosphorylase  b (92 kD), BSA (69 kD), 
OVA (46 kD), carbonic anhydrase (30 kD), and 
trypsin inhibitor (21 kD) are indicated in lane a. 
bridoma done to T lymphocytes from lymph nodes draining 
leishmanial footpad infections in vivo (week 5 of L.  major 
infection in C57BL/6 mice). Using two-color fluorescence 
flow cytometry, we determined that 5-25%  of the CD4 + 
lymph node lymphocytes express surface TNF (four experi- 
ments).  When  isolated by FACS  |  these TNF +  cells  in- 
duced in vitro antileishmanial effects in infected macrophages 
(46.3  _+ 5.8%, reduction in amastigotes per 100 macrophages 
compared to controls with no lymphocytes added; mean  _+ 
SE, three determinations; three separate experiments), effects 
that were diminished (by 52.3%) in the presence of anti-TNF 
antibody. 
The results of these studies indicate that CD4 + T  lym- 
phocytes, like macrophages  (13,  14),  CD8 +  (15) and un- 
classified peripheral blood T  lymphocytes (23),  can express 
a membrane-associated form of TNF. Furthermore, our studies 
suggest that the surface TNF can induce antileishmanial de- 
fense in macrophages through a cell contact-dependent mech- 
anism. The antigenic specificity (24, 25) and genetic restric- 
tion  (7,  26)  characteristic of the contact-mediated defense, 
which we have previously reported, indicates that CD4 § T 
lymphocyte  membrane-anchored  TNF  can  only  exert  a 
macrophage-activating influence in a highly restricted manner. 
This contrasts with the more promiscuous influence of soluble 
MAFs in host defense (3).  Since soluble TNF  has  a broad 
range of biological activities,  some of which are deleterious 
to the host (12), the more precisely targeted delivery of this 
effector molecule to infected macrophages may be beneficial. 
Moreover, we have observed that inflammatory macrophages 
that are relatively refractory to soluble MAF-mediated acti- 
vation of antileishmanial defense are fully susceptible to cell 
contact-mediated activation (6). Additionally, there exist cer- 
tain strains of L.  mexicana whose growth is not inhibited 
in resident macrophages cultured in the presence of soluble 
MAFs but is inhibited when the macrophages are cocultured 
with the effector lymphocytes (27).  Thus, the physiological 
consequences in infected macrophages of interactions with 
CD4 + T  lymphocyte membrane-anchored TNF may differ 
significantly from those induced by soluble lymphokines. Our 
observations  emphasize  the  need  to  evaluate  membrane- 
membrane interactions between CD4 + T  lymphocytes and 
macrophages not only in antigen presentation, but also  in 
effector functions of these lymphocytes. 
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